Found: 15
Select item for more details and to access through your institution.
Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 3, p. 258, doi. 10.1002/cpdd.289
- By:
- Publication type:
- Article
P-591: Effect of orlistat in patients with hypertension and either high or normal fasting insulin levels<sup>*</sup>.
- Published in:
- American Journal of Hypertension, 2001, v. 14, p. 227A, doi. 10.1016/S0895-7061(01)01898-2
- By:
- Publication type:
- Article
Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2005, v. 293, n. 23, p. 2873, doi. 10.1001/jama.293.23.2873
- By:
- Publication type:
- Article
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
- Published in:
- 2004
- By:
- Publication type:
- journal article
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study.
- Published in:
- Diabetes Care, 2004, v. 27, n. 1, p. 155, doi. 10.2337/diacare.27.1.155
- By:
- Publication type:
- Article
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 6, p. 675, doi. 10.1002/jcph.640
- By:
- Publication type:
- Article
Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 5, p. 548, doi. 10.1002/jcph.617
- By:
- Publication type:
- Article
Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial).
- Published in:
- Diabetes Therapy, 2012, v. 3, n. 1, p. 1, doi. 10.1007/s13300-012-0013-8
- By:
- Publication type:
- Article
Comparative Evaluation of Fecal Fat Excretion Induced by Orlistat and Chitosan.
- Published in:
- Obesity (19307381), 2001, v. 9, n. 6, p. 364, doi. 10.1038/oby.2001.47
- By:
- Publication type:
- Article
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
- Published in:
- 2013
- By:
- Publication type:
- journal article
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 3, p. 498, doi. 10.2337/dc12-0709
- By:
- Publication type:
- Article
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).
- Published in:
- 2012
- By:
- Publication type:
- journal article
Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment.
- Published in:
- Diabetes Care, 2012, v. 35, n. 3, p. 485, doi. 10.2337/dc11-1942
- By:
- Publication type:
- Article
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone.
- Published in:
- Diabetes Care, 2009, v. 32, n. 7, p. 1237, doi. 10.2337/dc08-1961
- By:
- Publication type:
- Article